TABLE 1.

Summary of VEEV-GP immunogenicity and efficacy mouse study

Challenge virus and route	VRP type	PRNT80a		IgG titera		Survival rateb	% survival
		Day 28	Day 63	Day 28	Day 63
VEEV-IAB
Subcutanteous	VEEV	23	686	3,051	113,130	10/10	100
	V/W/E	30	844	1,005	52,431	10/10	100
	Mock	20	20	33	33	2/5	40
	HIV Gag	20	20	33	33	10/10	100
Aerosol	VEEV	25	46	4,677	90,814	10/10	100
	V/W/E	26	92	2,167	90,814	10/10	100
	Mock	20	20	33	33	0/5	0
	HIV Gag	20	20	33	41	1/10	10
VEEV-IE
Subcutanteous	VEEV	20	21	3,014	65,315	10/10	100
	V/W/E	20	25	1,251	58,520	10/10	100
	Mock	20	20	33	33	0/5	0
	HIV Gag	20	21	33	33	4/10	40
Aerosol	VEEV	34	130	466	19,507	10/10	100
	V/W/E	33	121	300	17,477	10/10	100
	Mock	33	20	33	41	0/5	0
	HIV Gag	33	23	33	64	3/10	30
VEEV-IIIA, aerosol	VEEV	20	28	1,740	90,814	10/10	100
	V/W/E	20	25	647	46,976	10/10	100
	Mock	20	20	33	80	0/5	0
	HIV Gag	20	25	33	173	0/10	0

^aPRNT₈₀ and IgG titer are the reciprocal of the endpoint dilution.

^bNumber of survivors/total number of mice in group.